title: [Onset feature and efficacy of early interventional treatment of Artemisia pollinosis].
abstract: OBJECTIVE
  To analyze the clinical feature and treatment methods of Artemisia pollinosis.
  
  
  METHODS
  Skin prick test results of 14 426 cases from Beijing Tongren hospital and pollen concentration of Beijing observatory from 2007 to 2011 were analyzed to identify the clinical feature of Artemisia pollinosis patients and its correlation with the pollen concentration. Patients were given leukotriene receptor antagonists (Montelukast) for 2 weeks, followed by 4 weeks of mometasone furoate nasal spray (EIT group: n = 21), or only 4 weeks of mometasone furoate nasal spray (POT group: n = 16). The nasal symptom score was compared between 2 groups.SPSS 16.0 software was used to analyze the data.
  
  
  RESULTS
  Artemisia pollinosis accounted for 30.8% (4 442/14 426) of all SPT positive allergic rhinitis patients, and most Artemisia SPT positive results were strong positive(3 793/4 442, 85.4%); onset age peak of Artemisia pollinosis patients was at the age of 19 to 30, onset time concentrated in August to September, was consistent with the peak period of Artemisia pollen concentration; EIT treatment using leukotriene receptor antagonists two weeks before pollen season significantly improved sneeze, sniveling and rhinocnesmus symptoms (t value was 3.28, 3.92, 3.09, respectively, all P < 0.01) compared with post-onset treatment (POT). But nasal obstruction and cough symptoms had no significant difference between two groups (t value was 0.85, 1.52, respectively, all P > 0.05).
  
  
  CONCLUSIONS
  Artemisia pollen is the main pollen allergen in Beijing, EIT treatment was effective to pollinosis.
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Key Laboratory of Nasal diseases, Beijing Institute of Otorhinolaryngology, Beijing 100730, China.
authors.forename: Yuhui
authors.initials: Y
authors.lastname: Ouyang
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Key Laboratory of Nasal diseases, Beijing Institute of Otorhinolaryngology, Beijing 100730, China.
authors.forename: Erzhong
authors.initials: E
authors.lastname: Fan
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Key Laboratory of Nasal diseases, Beijing Institute of Otorhinolaryngology, Beijing 100730, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Li
authors.affiliation: Department of Otorhinolaryngology Head and Neck Surgery, Beijing TongRen Hospital, Capital Medical University, Key Laboratory of Nasal diseases, Beijing Institute of Otorhinolaryngology, Beijing 100730, China. Email: dr.luozhang@gmail.com.
authors.forename: Luo
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000085:Acetates / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000485:Allergens / Q000276:immunology*; D019306:Artemisia; D002648:Child; D002681:China; D003521:Cyclopropanes; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D011058:Pollen / Q000276:immunology*; D011244:Pregnadienediols / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D006255:Rhinitis, Allergic, Seasonal / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control*; D012621:Seasons; D013440:Sulfides; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000085:Acetates; D000485:Allergens; D003521:Cyclopropanes; D011244:Pregnadienediols; D011804:Quinolines; D013440:Sulfides; D000068656:Mometasone Furoate; C093875:montelukast